

## Maureen Rurka To Discuss Challenging Patents on Reference Drugs at ACI's Summit on Biosimilars & Innovator Biologics

JUNE 28-29, 2022

Winston & Strawn Partner Maureen Rurka spoke at the 13<sup>th</sup> Summit on Biosimilars & Innovator Biologics, June 28-29, in Boston, MA.

The summit—which attracts distinguished speakers, including leading in-house counsel and representatives from key government agencies and trade associations—explored the contours of the rapidly changing landscape for biosimilars and innovator biologics.

On June 28, Maureen spoke on a panel titled “Challenging Patents on Reference Drugs: Litigation Strategies in the IPR Forum.”

Among other topics, the interactive panel covered:

- Reducing risk by challenging patents in advance of launching biosimilars at risk
- Understanding the advantages for applicants to resolve prior art invalidity disputes via IPRs
- Establishing standing to appeal in an IPR in connection with BPCIA and the FDA approval process for biosimilars
- Anticipating an answer to the unresolved question as to how much investment is required in the biosimilar context under Article III to establish standing
- Appreciating the timing for applicants to file petitions for IPRs relative to filing BLAs and BPCIA litigation
- Analyzing biosimilars IPR filings and recent PTAB decisions

[Learn more about Winston's Patent Litigation Practice.](#)

1 Min Read

### Related Locations

Chicago

## Related Capabilities

Patent Litigation

Medical Devices


Health Care

## Related Regions

North America

## Related Professionals

---



Maureen Rurka